 Doxorubicin
"Doxorubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
| Descriptor ID |
D004317
|
| MeSH Number(s) |
D02.455.426.559.847.562.050.200.175 D04.615.562.050.200.175 D09.408.051.059.200.175
|
| Concept/Terms |
Adriblastin- Adriblastin
- Adriblastine
- Adriblastina
- Adriablastine
- Adriablastin
DOXO-cell- DOXO-cell
- DOXO cell
- Urokit Doxo-cell
- Urokit Doxo cell
|
Below are MeSH descriptors whose meaning is more general than "Doxorubicin".
Below are MeSH descriptors whose meaning is more specific than "Doxorubicin".
This graph shows the total number of publications written about "Doxorubicin" by people in this website by year, and whether "Doxorubicin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 | | 1997 | 3 | 1 | 4 | | 1998 | 1 | 4 | 5 | | 1999 | 1 | 2 | 3 | | 2000 | 1 | 1 | 2 | | 2001 | 1 | 7 | 8 | | 2002 | 1 | 3 | 4 | | 2003 | 0 | 2 | 2 | | 2004 | 2 | 1 | 3 | | 2006 | 2 | 6 | 8 | | 2007 | 2 | 6 | 8 | | 2008 | 0 | 6 | 6 | | 2009 | 4 | 6 | 10 | | 2010 | 0 | 5 | 5 | | 2011 | 2 | 5 | 7 | | 2012 | 4 | 6 | 10 | | 2013 | 2 | 6 | 8 | | 2014 | 2 | 8 | 10 | | 2015 | 2 | 5 | 7 | | 2016 | 6 | 5 | 11 | | 2017 | 3 | 9 | 12 | | 2018 | 4 | 10 | 14 | | 2019 | 2 | 11 | 13 | | 2020 | 2 | 8 | 10 | | 2021 | 4 | 9 | 13 | | 2022 | 1 | 6 | 7 | | 2023 | 5 | 9 | 14 | | 2024 | 5 | 7 | 12 | | 2025 | 5 | 6 | 11 | | 2026 | 4 | 2 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Doxorubicin" by people in Profiles.
-
Mazhindu T, Nyangwara VA, Borok MZ, Masimirembwa C, Flaig T, Campbell TB, Ndlovu N. Doxorubicin-induced early-onset chronic progressive cardiotoxicity, pharmacogenetics and survival among breast cancer patients in Zimbabwe. S Afr Med J. 2026 Jun 02; 116(5):e3655.
-
Darrah MA, Mahoney SA, Venkatasubramanian R, VanDongen NS, Ludwig KR, Seals DR, Rossman MJ, Clayton ZS. Fisetin Supplementation Attenuates Premature Vascular Aging Induced by Doxorubicin via Suppression of Cellular Senescence and Mitochondrial Oxidative Stress. Aging Cell. 2026 May; 25(5):e70535.
-
Abramson JS, Straus DJ, Bartlett NL, Burke JM, Lynch RC, Domingo Domenech E, Hess B, Schuster SR, Linhares Y, Gandhi M, Shah HR, Jurczak W, Re A, Hahn U, Prince HM, Guo W, Davis G, Ho L, Fanale M, Yasenchak CA, Lee HJ. Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma. Blood. 2026 Apr 09; 147(15):1713-1722.
-
Flerlage JE, Feraco AM, Zhou Y, Zheng Y, Liang J, Lucas JT, Friedmann AM, Weinstein HJ, Yock TI, Shulkin B, Kaste SC, Marks LJ, Ehrhardt MJ, Dixon SB, Howard S, de Alarcon P, Luna-Fineman S, Geddis A, Larsen EC, Marcus K, Billett AL, Donaldson SS, Hudson MM, Metzger ML, Krasin MJ, Link MP. Dose-dense chemotherapy enables elimination of RT for the majority of low-risk pediatric Hodgkin lymphomas: PHC study HOD08. Blood. 2026 Mar 19; 147(12):1289-1301.
-
Izaias JE, Sales AO, Ono BE, Rodrigues TS, Silva GMPS, Pentagna PS, Albuquerque ALP, Folchini FN, Colombo FMC, Irigoyen MCC, Rodrigues AG, Negrão CE, Testa L, Rocha NG, Rocha HNM, Texeira GF, Nóbrega ACLD, Miyaguti NAS, Silva AAR, Porcari AM, Nascimento-Filho AV, De Angelis K, Craighead DH, Clayton ZS, Ludwig KR, Rossman MJ, Seals DR, Moll-Bernardes R, Sales ARK. Sympathetic Neural Overactivation, Vascular Dysfunction, and Exercise Intolerance in Long-Term Survivors of Breast Cancer Treated With Doxorubicin and Trastuzumab-Based Chemotherapy. J Am Heart Assoc. 2026 Mar 17; 15(6):eJAHA2025048047T.
-
Chen XL, Tharp KM, Ojalill M, Ozmadenci D, Boyer A, Haanen TJ, Lawson C, Lee HJ, Xia M, Tahon E, Zhang Y, Minor C, Khan SU, Anderson CC, Nemkov T, Rose M, Estrada MV, Molinolo AA, Warren E, Penalosa P, Eskander RN, McHale MT, Wang SE, Connolly DC, Fisch KM, Stupack DG, Schlaepfer DD. FAK inhibition in ovarian cancer releases omega-3 fatty acids to program CXCL13-producing anti-tumor resident peritoneal macrophages. Cell Rep. 2026 Mar 24; 45(3):117009.
-
Smuder AJ, Doerr V, Jacintho Moritz CE, Li J, Nguyen BL. Mitochondrial Transporter ABCB10 Protects Against Doxorubicin-Induced Respiratory Muscle Dysfunction Independent of Changes to Diaphragm Accumulation. J Cachexia Sarcopenia Muscle. 2026 Feb; 17(1):e70171.
-
Hess B, Moskowitz A, Davis JA, Strati P, Sawalha Y, Bakos J, Sorrell M, Ferreira AC, Escribano-Serrat S, De Castro M, Brooks TR, Hill BT, Shah GL, Falade AS, Merryman R, Kamdar M, Ip A, Nachar V, Bennett JG, Lux N, Ahmed N, Hoffmann M, LaCasce A. Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R. Haematologica. 2026 Apr 01; 111(4):1389-1395.
-
Venkatasubramanian R, Mahoney SA, Hutton DA, VanDongen NS, Brunt VE, Greenberg NT, Longtine AG, Brandt L, Beyer AM, Melov S, Rossman MJ, Seals DR, Clayton ZS. Cellular senescence mediates doxorubicin chemotherapy-induced vascular endothelial dysfunction: translational evidence of prevention with senolytic treatment. Am J Physiol Heart Circ Physiol. 2025 Dec 01; 329(6):H1672-H1683.
-
Clayton ZS, Nguyen BL, Venkatasubramanian R, Kabos P. Exercise to Mitigate Premature Vascular Aging After Doxorubicin Breast Cancer Therapy. Exerc Sport Sci Rev. 2025 Oct 01; 53(4):187-194.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|